Therapy News and Research

RSS

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Limit children's media exposure to the Colorado shooting tragedy

In the wake of the tragic shooting at the screening of The Dark Knight Rises in Aurora, Colo., parents should encourage their children to express their feelings and limit their media exposure to the tragedy, say experts from Children's Hospital Los Angeles.

21 Jul 2012

Anxiety in poor mothers not a psychiatric problem but a reaction to severe environmental deficits

Poor mothers are more likely to be classified as having the mental illness known as generalized anxiety disorder (GAD) because they live in poverty - not because they are suffering from a psychiatric disorder, according to Rutgers researchers.

21 Jul 2012

WHO identifies key actions countries can take to prevent HIV infections among people who inject drugs

WHO has identified four key actions countries can take to prevent viral hepatitis B and C among people who inject drugs. Of the estimated 16 million people who inject drugs worldwide, it is estimated that 10 million are infected with hepatitis C. An additional 1.2 million are infected with hepatitis B.

21 Jul 2012

IAS releases 'road map' to find HIV cure ahead of AIDS 2012 Conference

The International AIDS Society (IAS) on Thursday in Washington, D.C., "released what they call a road map for research toward a cure for HIV -- a strategy for global teams of scientists to explore a number of intriguing leads that just might, years from now, pan out," the Associated Press reports (Neergaard, 7/20).

21 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

CBT, pharmacologic interventions decrease depressive symptoms in cancer patients

Despite guidelines recommending screening for depression in cancer patients, it's been unclear whether interventions designed to treat this depression are effective. A study by the University of Colorado Cancer Center and other institutions, published in the Journal of the National Cancer Institute, changes that.

21 Jul 2012

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

On the eve of the XIX International AIDS Conference in Washington, DC, the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, announces a new collaboration with Indian drug manufacturer Cipla to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

21 Jul 2012

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Montefiore physician to develop tablet computer app for children with cochlear implants

Elena Willis, MD Resident Physician, Department of Otorhinolaryngology - Head and Neck Surgery, Montefiore Medical Center, has been awarded a $10,000 Resident Research Grant by The American Academy of Otolaryngology - Head and Neck Surgery, sponsored by The Oticon Foundation, to develop a tablet computer app to help improve the speech of children with cochlear implants.

20 Jul 2012

CPAP benefits extend to mild OSA patients

The use of continuous positive airway pressure treatment, an effective option for severe obstructive sleep apnea, should be extended to sleepy patients with milder OSA, say US researchers.

20 Jul 2012

Poststroke speech therapy ‘should be reorganized’

Results of the randomized ACT NoW trial show no benefit of “enhanced” over “everyday” communication therapy for patients with dysarthria resulting from stroke.

20 Jul 2012

Study on relationship between pain and higher brain functions

University of Texas Medical Branch at Galveston professor Volker Neugebauer has been awarded a four-year, $1.36 million grant by the National Institute of Neurological Disorders and Stroke to conduct an innovative study of the relationship between pain and parts of the brain associated with cognitive thought and emotional response.

20 Jul 2012

Therapy News and Research

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

BioDiem presents positive findings of their eye disease drug at international conference

Limit children's media exposure to the Colorado shooting tragedy

Anxiety in poor mothers not a psychiatric problem but a reaction to severe environmental deficits

WHO identifies key actions countries can take to prevent HIV infections among people who inject drugs

IAS releases 'road map' to find HIV cure ahead of AIDS 2012 Conference

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

New CHAIT initiative on development of novel immunological therapeutic interventions

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Experts examine host recognition of Staphylococcus and E.coli bacteria

CBT, pharmacologic interventions decrease depressive symptoms in cancer patients

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

uniQure receives positive recommendation from EMA CHMP for Glybera

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

Montefiore physician to develop tablet computer app for children with cochlear implants

CPAP benefits extend to mild OSA patients

Poststroke speech therapy ‘should be reorganized’

Study on relationship between pain and higher brain functions

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News